Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity.
暂无分享,去创建一个
Stefan Güssregen | Hans Matter | Armin Bauer | Marc Nazaré | H. Matter | H. Schreuder | A. Bauer | M. Nazaré | M. Urmann | David W Will | Michael Wagner | Matthias Urmann | Herman Schreuder | Kurt Ritter | Volkmar Wehner | K. Ritter | S. Güssregen | D. W. Will | M. Wagner | V. Wehner
[1] S. Tsuzuki,et al. The interaction of benzene with chloro- and fluoromethanes: Effects of halogenation on CH/π interaction , 2002 .
[2] Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand. , 2004, Bioorganic & medicinal chemistry letters.
[3] Hans Matter,et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. , 2005, Journal of medicinal chemistry.
[4] J. Malone,et al. Attractive intramolecular edge-to-face aromatic interactions in flexible organic molecules. , 2001, Accounts of chemical research.
[5] Bin Ye,et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. , 2002, Biochemistry.
[6] A. Bondi. van der Waals Volumes and Radii , 1964 .
[7] Wechselwirkungen mit aromatischen Ringen in chemischen und biologischen Erkennungsprozessen , 2003 .
[8] F. Leroux. Atropisomerism, Biphenyls, and Fluorine: A Comparison of Rotational Barriers and Twist Angles , 2004, Chembiochem : a European journal of chemical biology.
[9] W. Hagmann,et al. The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.
[10] Manfred Kansy,et al. Fluorine Interactions at the Thrombin Active Site: Protein Backbone Fragments HCαCO Comprise a Favorable CF Environment and Interactions of CF with Electrophiles , 2004, Chembiochem : a European journal of chemical biology.
[11] F. Diederich,et al. Interactions with aromatic rings in chemical and biological recognition. , 2003, Angewandte Chemie.
[12] N. Kitteringham,et al. Metabolism of fluorine-containing drugs. , 2001, Annual review of pharmacology and toxicology.
[13] Pierangelo Metrangolo,et al. Halogen bonding in supramolecular chemistry. , 2008, Angewandte Chemie.
[14] Martin Stahl,et al. Fluorine in Medicinal Chemistry , 2004, Chembiochem : a European journal of chemical biology.
[15] T. Dunning,et al. Electron affinities of the first‐row atoms revisited. Systematic basis sets and wave functions , 1992 .
[16] Sébastien Maignan,et al. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. , 2003, Journal of medicinal chemistry.
[17] Edward F. Valeev,et al. Estimates of the Ab Initio Limit for π−π Interactions: The Benzene Dimer , 2002 .
[18] Jing Zhang,et al. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors. , 2008, Journal of medicinal chemistry.
[19] Christopher W Murray,et al. Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.
[20] U. Singh,et al. A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .
[21] Andrew D Westwell,et al. The role of fluorine in medicinal chemistry , 2007, Journal of enzyme inhibition and medicinal chemistry.
[22] Eric Gouaux,et al. Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand‐binding core , 2003, The EMBO journal.
[23] Robin Taylor,et al. Organic Fluorine Hardly Ever Accepts Hydrogen Bonds , 1997 .
[24] Eric Westhof,et al. Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] L. J. Andrews. Aromatic Molecular Complexes of the Electron Donor-Acceptor Type. , 1954 .
[26] Thomas Lampe,et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. , 2005, Journal of medicinal chemistry.
[27] Paul Seiler,et al. A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: evidence for C-F...C=O interactions. , 2003, Angewandte Chemie.
[28] Grégori Gerebtzoff,et al. Halogenation of Drugs Enhances Membrane Binding and Permeation , 2004, Chembiochem : a European journal of chemical biology.
[29] G. Klebe,et al. pH‐Dependent Binding Modes Observed in Trypsin Crystals: Lessons for Structure‐Based Drug Design , 2002 .
[30] Colin McMartin,et al. QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..
[31] S. Brady,et al. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. , 1998, Journal of medicinal chemistry.
[32] J. Doyon,et al. Models of F.H contacts relevant to the binding of fluoroaromatic inhibitors to carbonic anhydrase II. , 1999, Organic letters.
[33] Pierangelo Metrangolo,et al. Halogenbrücken in der supramolekularen Chemie , 2008 .
[34] Gerhard Klebe,et al. Relibase: design and development of a database for comprehensive analysis of protein-ligand interactions. , 2003, Journal of molecular biology.
[35] S. Tsuzuki,et al. Origin of attraction and directionality of the pi/pi interaction: model chemistry calculations of benzene dimer interaction. , 2002, Journal of the American Chemical Society.
[36] Pavel Hobza,et al. Potential Energy Surface for the Benzene Dimer. Results of ab Initio CCSD(T) Calculations Show Two Nearly Isoenergetic Structures: T-Shaped and Parallel-Displaced , 1996 .
[37] K. Sekar,et al. C-halogen…π interactions in proteins: a database study , 2003 .
[38] G. Cruciani,et al. Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. , 2004, Journal of medicinal chemistry.
[39] Hans Matter,et al. Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. , 2005, Journal of medicinal chemistry.
[40] Pavel Hobza,et al. Structure and Properties of Benzene-Containing Molecular Clusters - Nonempirical Ab-Initio Calculations and Experiments , 1994 .
[41] Stephen K. Burley,et al. Dimerization energetics of benzene and aromatic amino acid side chains , 1986 .
[42] Manfred Kansy,et al. A Fluorine Scan at the Catalytic Center of Thrombin: CF, COH, and COMe Bioisosterism and Fluorine Effects on pKa and log D Values , 2006, ChemMedChem.
[43] P Voth Regier Andrea and Ho Shing,et al. The role of halogen bonding in inhibitor recognition and binding by protein kinases. , 2007 .
[44] K. Kitaura,et al. Cl–π interactions in protein–ligand complexes , 2008, Protein science : a publication of the Protein Society.
[45] S. F. Boys,et al. The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors , 1970 .
[46] H. M. Vinkers,et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.
[47] H. Schneider,et al. Non-covalent interactions of organic halogen compounds with aromatic systems: Analyses of crystal structure data , 2005 .
[48] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[49] G A Petsko,et al. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.
[50] Bernard J. Ransil,et al. Studies in Molecular Structure. IV. Potential Curve for the Interaction of Two Helium Atoms in Single‐Configuration LCAO MO SCF Approximation , 1961 .